National Medical Insurance Bureau: The first domestic new crown oral medication is temporarily included in medical insurance reimbursement

The reporter learned from the National Medical Insurance Bureau that in accordance with the relevant provisions of basic medical insurance, in order to better protect the needs of diagnosis and treatment, all medicines that are included in the new coronary pneumonia diagnosis and treatment plan can be temporarily included in the scope of medical insurance payment.

On August 9, the National Health and Health Commission has issued a notice to include Azf's fixed slices into the new type of coronary virus pneumonia diagnosis and treatment plan. Therefore, the medical insurance fund can be paid in accordance with regulations when using the drug.

More news

The first domestic new crown oral medicine has arrived in Hainan and Xinjiang

At the end of last month, the first domestic new crown small molecule was taken by the first domestic new crowned small molecules, and Azf has been applied.

On the evening of August 11, Fosun Pharmaceutical (600196.SH; 02196.HK) announced that its united real biological response to the needs of governments in various localities, urgently deployed Azf's fixing to assist in the country in many places. Hainan, Xinjiang and other places.

At present, the pricing of Azf's fixed tablet has been clear. Compared with the new crown therapy drugs currently on the market, the price of the drug has a great advantage. According to reports, according to the price of medical insurance hanging networks in various places, Azf's fixed price is priced at 270 yuan per bottle, 35 tablets per bottle, and 1 mg per piece.

In the process of treating the new crown, the approved certificate approved by Azf was used to treat adult patients with COVID-19). The usage is swallowed in an empty stomach, 5mg each time, once a day, the course of treatment is not more than 14 days. If you take a maximum of 14 days, a course of treatment costs about 540 yuan.

- END -